73 articles
Josefa Briceno, M.D., Medical Head for the DNA Damage Response Franchise in US Medical Affairs at AstraZeneca discusses the recent FDA approval of LYNPA...
Geoffrey Eubank, M.D., Medical Director of the Mid Ohio MS Center at OhioHealth Neurological Physicians, discusses 2 Phase lll clinical trials of Enspry...
Kathleen Hawker, M.D., Group Medical Director, Neuroscience at Genentech discusses the recent FDA approval of Enspryng™ (satralizumab-mwge) and the fi...
David Spetzler, President and Chief Scientific Officer at Caris Life Sciences® discusses the partnership with Elevation Oncology to identify patients f...
RJ Tesi, CEO of INmune Bio, Inc., a clinical stage immuno-oncology company targeting neuroinflammation to fight brain disease, discusses positive data p...
Ayman Al-Hendy, MD, discusses the recent FDA approval of AbbVie’s ORIAHNN™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsul...
Mark Erlander, CEO of Cardiff Oncology discusses their lead drug candidate Onvansertib and the three active clinical trials in colorectal cancer, acute ...
Vice President and Gastroenterology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC, talks about data fro...
Tzvia Bader, co-founder, and CEO talks about TrialJectory, a first-of-its-kind AI-powered platform that uses self-reported clinical data to match cancer...
Sinai, New York discusses Janssen's announcement of their new two-year data from the long-term extension of the Phase 3 UNIFI study of STELARA® (usteki...